U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C12H16N2O2
Molecular Weight 220.2676
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of ELTOPRAZINE

SMILES

C1CN(CCN1)C2=CC=CC3=C2OCCO3

InChI

InChIKey=WVLHGCRWEHCIOT-UHFFFAOYSA-N
InChI=1S/C12H16N2O2/c1-2-10(14-6-4-13-5-7-14)12-11(3-1)15-8-9-16-12/h1-3,13H,4-9H2

HIDE SMILES / InChI

Molecular Formula C12H16N2O2
Molecular Weight 220.2676
Charge 0
Count
MOL RATIO 1 MOL RATIO (average)
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description

Eltoprazine, a 5-HT1A/B receptor partial agonist, was created by Duphar in the 1980s (as DU-28853) and was subsequently developed by Solvay to treat pathological aggression. This drug is in clinical development for the treatment of Parkinson's disease levodopa-induced dyskinesia (PD-LID), Alzheimer's aggression and adult attention deficit hyperactivity disorder (adult ADHD). In addition, was shown, that the drug could be useful for normalizing prefrontal cognitive abilities, reducing aggression and impulsivity, and improving cognitive function in schizophrenia.

Originator

Approval Year

Targets

Primary TargetPharmacologyConditionPotency
40.0 nM [Ki]
52.0 nM [Ki]

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown
Primary
Unknown
Primary
Unknown
Primary
Unknown

Cmax

ValueDoseCo-administeredAnalytePopulation
62.9 ng/mL
30 mg single, oral
ELTOPRAZINE plasma
Homo sapiens

AUC

ValueDoseCo-administeredAnalytePopulation
746 ng × h/mL
30 mg single, oral
ELTOPRAZINE plasma
Homo sapiens

T1/2

ValueDoseCo-administeredAnalytePopulation
5.9 h
30 mg single, oral
ELTOPRAZINE plasma
Homo sapiens
9.3 h
8 mg single, intravenous
ELTOPRAZINE plasma
Homo sapiens

PubMed

Sample Use Guides

In Vivo Use Guide
eltoprazine HCl 2.5; 5 or 7.5 mg capsules to be taken orally b.i.d. (ie, 5 mg/day) for 3 weeks
Route of Administration: Oral
In Vitro Use Guide
There was localized and characterized the binding sites of [3H]eltoprazine in the rat brain. The binding of [3H]eltoprazine to whole tissue sections was saturable and revealed an apparent dissociation constant (Kd) of 11 nM. Autoradiographic studies demonstrated a widespread distribution of [3H]eltoprazine binding sites throughout the brain. Specific [3H]eltoprazine binding was completely displaced by 5-HT; conversely, unlabeled eltoprazine reduced [3H]5-HT binding to the levels of non-specific binding. The pharmacological and anatomical data indicate that eltoprazine binds to 5-HT1A, 5-HT1B and to a lesser extent to 5-HT1C binding sites in the rat brain.
Substance Class Chemical
Record UNII
510M006KO6
Record Status Validated (UNII)
Record Version